Lancet Respiratory Medicine

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	998
Concerns regarding a suggested long COVID paradigm – Authors' reply	492
Rituximab for connective tissue disease-associated interstitial lung disease	383
Broad protection from SARS-CoV-2 variants without antigen matching	307
European Respiratory Society International Congress 2022	246
The burden of tuberculosis in Libya	246
US Senate committee investigates asthma inhaler prices	243
Major gaps in childhood pneumonia research priorities remain	231
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	224
Opioids bring peace to patients with IPF cough	217
Correction to Lancet Respir Med 2024; 12: 129–40	217
Video laryngoscopy is not the nemesis of direct laryngoscopy	211
Postoperative CPAP after major abdominal surgery	204
Impact of Myanmar's earthquake on respiratory health	192
Predicted bodyweight—a misleading metric for tidal volume titration?	189
Concerns about PRISm	187
Eat or heat: fuel poverty and childhood respiratory health	185
Predatory publishers appear in PubMed (and your inbox)	183
Australia bans engineered stone to prevent silicosis	181
Chronic obstructive pulmonary disease: 10 years of precision-guided success	178
Interstitial lung disease: a decade of progress and hope	177
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	175
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	174
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	170
Long COVID: systemic inflammation and obesity as therapeutic targets	170

Thoracentesis: an old story and some new sources	163
FLiRTing with danger as SARS-CoV-2 variants evolve	162
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	161
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	159
GOLD report: 2022 update	158
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	156
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	156
Advancing precision medicine for acute respiratory distress syndrome	153
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	146
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	144
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	144
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	142
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	142
Vaccination in the world's top athletes	142
Correction to Lancet Respir Med 2025; 13: 244–55	139
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	138
Correction to Lancet Respir Med 2021; 9: 1275–87	138
Trump administration decimates worker health oversight	136
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	134
Correction to Lancet Respir Med 2022; 10: 972–84	128
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	124
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	123
Claudio Castanos—leader in cystic fibrosis care in Argentina	123
Priorities for NICE in health and social care	123
US EPA signals renewed regulatory scrutiny of toxic air pollution	121
Solid and semi-solid perspectives in thoracic surgery	119
Improving lifelong respiratory health after preterm birth	115
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	114
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m	113
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	112
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	111
Chronic cough as a disease: implications for practice, research, and health care	110
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	106
Extracorporeal cardiopulmonary resuscitation: not why, but how	105
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	105
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	105
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	104
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	101
Genetic associations and lung function in IPF: unexpected answers, persistent questions	99
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	98
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	98
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	98
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	96
Association of SARS-CoV-2 infection and persistence with long COVID	96
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	94
Unveiling a hidden phenotype of early tuberculosis	92
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	92
Spirometry in female individuals – Authors' reply	91
Health effects from climate-driven events: lessons learnt	91
Choice overload for RSV prevention—how to form your opinion	90

Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	89
Pre-COPD: an evolving concept with practice potential	88
Tackling tuberculosis: what lies beneath the surface?	85
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	84
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	83
Correction to Lancet Respir Med 2023; 11: 1064–74	83
Underappreciated causes of obstructive lung disease	81
COP27 Climate Change Conference: urgent action needed for Africa and the world	81
Opioid use and sleep apnoea	81
Liberal or restrictive transfusion for VV ECMO	79
Realignment of clinical research after the COVID-19 era	78
Pooled testing for TB: revisiting a cost-saving innovation	78
Trouble with promoting lung cancer screening in never-smokers	75
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	73
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	73
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	73
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	72
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	71
Clean air, climate targets, and respiratory health in Europe	70
COPD: a complex, multifactorial, but preventable disease?	69
Developments and priorities in bronchiectasis research	69
The Ramp to Nowhere: When hope slips through the cracks in care	69
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	68
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	68
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	67
Early-life respiratory syncytial virus disease and long-term respiratory health	65
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	64
Treating acute respiratory illness: the need to be proactive	64
Collateral caring	64
The recent explosion in snortable energy powder consumption	61
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	60
Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer	59
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	57
COVID-19—an infectious disease in the top five causes of death in Australia	57
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	57
Society of Critical Care Medicine Critical Care Congress 2023	57
E-cigarette company tactics in sports advertising	57
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	57
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	56
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	56
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	56
Home monitoring in interstitial lung diseases	55
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	55
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	53
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	53
Managing tuberculosis before the onset of symptoms	53
Wildfires in southern California: concerns for lung health	52
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	52
Continuing ECMO with no possible transition to recovery or transplant	52
Pioneering a paradigm shift in asthma management: remission as a treatment goal	52
Breathing barriers: bridging lung health, research, and awareness	52
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	52
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	52
Moving forward in IPF: lessons learned from clinical trials	52
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	51
Rise in group A streptococcal infections in England	51
EVEREST and the eosinophil paradox – Authors' reply	50
Common and rare variants and survival in idiopathic pulmonary fibrosis	50
Remission in chronic cough: an achievable target?	50
Trial emulation with observational data in cystic fibrosis	50
The importance of post-tuberculosis morbidity in high-income countries	50
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	50
NUTRIREA-3: where to next?	49
Correction to Lancet Respir Med 2025; 13: 800–08	49
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	49
What is adequate preoxygenation? – Authors' reply	49
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	48
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	48
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	48
General population-based lung function trajectories over the life course: an accelerated cohort study	48
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	47
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	47
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	47
Tackling the global burden of lung disease through prevention and early diagnosis	47
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	47
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	46
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	46
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	46
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	45
ECMO: more than just a bridge over troubled waters?	45

Reflections 5 years on from the approval of ETI therapy	45
Use of lung-cancer trends for global and public health priorities	44
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	43
Community-acquired pneumonia: the best candidates for clarithromycin	43
Stubble: the Farmer's Bane	43
US Senate announces planned gun reforms after latest school shooting	42
The upcoming influenza season and protection from vaccines	42
Flavia Machado—a Latin American leader in sepsis	41
Postoperative CPAP after major abdominal surgery – Authors' reply	41
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	41
Guidelines might help reduce the burden of asthma in African children	41
Lifting the veil on humour and anaesthetics	41
Neomi Shah—cracking the conundrum of sleep disorders	40
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	40
Surviving sepsis with multiple serious complications	39
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	39
Oral corticosteroids for acute preschool wheeze	39
Correction to Lancet Respir Med 2024; 12: 544–55	38
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial	38
European Lung Cancer Congress 2024	38
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	38
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	37
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	37
How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?	36
Management of prematurity-associated lung disease from infancy through to adulthood	36
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	36
Ventilation during surgery: moving away from one-size-fits-all	36
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	36
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	35
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	35
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	35
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	35
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	34
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	34
Fighting sepsis: still a long way to go	34
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	33
Correction to Lancet Respir Med 2025; 13: 318–26	33
The carbon footprint of inhaled medications in Australia	33
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	33
International guideline recommendations and eligibility criteria for home oxygen therapy	33
Discussions on VT4COVID	32
Convalescent plasma in outpatients with COVID-19	31
It is time to include real-world effectiveness data on medicinal product labels	31
Concerns regarding a suggested long COVID paradigm	31
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	30
Correction Lancet Respir Med 2022; 10: 937–48	30
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	30
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	29
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	29
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	29
US EPA strengthens PM2·5 air pollution limits	29
Lockdown as the mother of invention: disruptive technology in a disrupted time	29
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	28
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	28
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	27
Remdesivir saves lives. Were 3 years needed to learn that?	27
Tuberculosis prevalence: beyond the tip of the iceberg	27
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	27
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	26
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	26
How Glasgow's 1957 tuberculosis screening programme could help countries today	26
Neurofilament light chain in post-cardiac arrest prognostication: from signal to strategy	26
Air pollution, climate change, and lung health in Europe	26
Home-based monitoring in chronic respiratory diseases: in search of Panacea	26
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	25
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	25
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	25
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	25
Living with spinal muscular atrophy while working in critical care	25
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	25
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	25
European Respiratory Society International Congress 2024	24
The future of paediatric acute respiratory distress syndrome	24
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	24
Opportunities and challenges of COPD tertiary prevention	24
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	23
What is next for BCG revaccination to prevent tuberculosis?	23
Navigating uncertainty: asthma biologics during pregnancy	23
Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI	23
Phenotypes of idiopathic pulmonary arterial hypertension	23
Chronic obstructive pulmonary disease: new therapies and old needs	23
Treatment strategy for EGFR mutated NSCLC	23
Tuberculosis, conflict, and displacement	22
Addressing the origins and health effects of small lungs	22
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	22
Volcanic eruption in Tonga and effects on respiratory health	22
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	22
Correction to Lancet Respir Med 2022; 10: 327–36	22
The Wuhan lockdown	21
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open	20
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	20
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	20
Can the positive findings from POD1UM-304 improve patient care worldwide?	20
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	19
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	19